SOURCE: Heartland Bridge Capital, Inc.

March 11, 2011 12:08 ET

Heartland Bridge Capital Announces Advisory Board Member

Marks the Initial Step in Creating a First Class Team of Advisors

MAHWAH, NJ--(Marketwire - Mar 11, 2011) - Heartland Bridge Capital (OTCBB: HLBC) announced today that Magdy Abdel-Malik, Ph.D., has become the first member of the Company's Advisory Board. This appointment signals the start of what the Company believes will be a superlative body of experts in the areas of strategic focus for the Company. Dr. Abdel-Malik is a highly reputed corporate innovation leader with extensive R&D and business development experience. This experience, combined with an unwavering commitment to innovative thinking, aimed at implementing the strategic vision needed to source, evaluate, acquire, and commercialize best-in-class life science emerging technologies should help accelerate Heartland's growth initiatives.

"The initiation of our Advisory Board is an exciting event, made even more so by my good fortune in being able to announce Dr. Abdel-Malik as the first member," said James F. Groelinger, Heartland's CEO. "His already-demonstrated ability to assist us in evaluating life science investment opportunities will only become increasingly valuable as the range and number of opportunities we examine multiply. Magdy has the experience and poise to support our efforts on the commercial side of consummating transactions, and the depth of training and expertise to accelerate the screening and due diligence aspects significantly. I look forward to a long, pleasurable, and successful association with him."

Upon joining the Advisory Board, Dr. Abdel-Malik said: "I'm pleased to join Heartland's Advisory Board. This is an exciting time as we pick up the pace of identifying, evaluating, and acquiring positions in exciting life science investment opportunities. Combined with its existing investments in the Myself® pelvic muscle trainer and in a novel medical applicator it is developing, and in the course of examining other equally exciting technologies, the Company has already shown a serious interest in life science investments."

Dr. Magdy Abdel-Malik currently serves as Founder and President of Quaestio Global Partners (, a management consultancy in the Healthcare and Life Sciences industries. Prior to founding Quaestio GP he served as Director of Global External Opportunities at Pfizer Consumer Healthcare.

About Heartland Bridge Capital, Inc.: Heartland Bridge Capital, Inc. (OTCBB: HLBC) is a newly organized public company that, in addition to managing its own operating entities, will participate in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world. HLBC will function as an owner, a product developer, and an investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, and life sciences. Additionally, HLBC will supplement the capabilities of its investment companies in non-financial areas to help them achieve their potential, thereby maximizing the value of the investment for HLBC's shareholders. See

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Heartland Bridge Capital, Inc. cautions that statements made in this news release relating to the appointment of Dr. Abdel-Malik and the business direction of the Company constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management. Actual results could differ materially from current projections or implied results. Heartland Bridge Capital, Inc. undertakes no obligation to revise these statements following the date of this news release.

For more information or to schedule an interview with James F. Groelinger, please contact him at (201) 512-8732 or email

Contact Information